Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / CBAY - CymaBay Therapeutics: Undiscovered Opportunity


CBAY - CymaBay Therapeutics: Undiscovered Opportunity

Summary

  • 100% technical buy signals.
  • 13 new highs and up 84.95% in the last month.
  • Wall Street price targets from $8 to $14.

The Chart of the Day belongs to the biopharma company CymaBay Therapeutics (CBAY). I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal, then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 11/15, the stock gained 64.85%.

CBAY Price vs 20,50,100 DMA ( )

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis ((PBC)), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart Technical Indicators:

  • 100% technical buy signals
  • 55.10+Weighted Alpha
  • 87.31% gain in the last year
  • Trend Seeker buy signal
  • Above its 20, 50 and 100 day moving averages
  • 13 new highs and up 84.45% in the last month
  • Relative Strength Index 86.77%
  • Recently traded at $6.05 with 50 day moving average of $3.85

Fundamental Factors:

  • Market Cap $513 million
  • Wall Street analysts have not given Revenue and Earnings projections

For further details see:

CymaBay Therapeutics: Undiscovered Opportunity
Stock Information

Company Name: CymaBay Therapeutics Inc.
Stock Symbol: CBAY
Market: NASDAQ
Website: cymabay.com

Menu

CBAY CBAY Quote CBAY Short CBAY News CBAY Articles CBAY Message Board
Get CBAY Alerts

News, Short Squeeze, Breakout and More Instantly...